MedImmune shares got a boost after the Maryland biotech announced the results of a new study showing some big advantages of FluMist over injected flu vaccines. Children under 5 receiving FluMist had 55 percent fewer cases of flu compared to a group getting the standard jab. FluMist is already approved for everyone who's 5 to 49.
It's all good news for MedImmune, which has struggled mightily to build a market for FluMist after initially registering a less-than-enthusiastic response from the public. MedImmune's execs right now may be spending more time mulling the news that Carl Icahn has accumulated a stake of 2.8 million shares in the biotech. Icahn recently spurred a shakeup [1] at ImClone after gaining seats on the board.
- read the report [2] on FluMist from the AP
Related Articles:
MedImmune touts new FluMist version. Report [3]
FDA approves refrigerated formulation of FluMist. Report [4]
MedImmune gets nod for new vaccine tech. Report [5]
Links:
[1] http://www.fiercebiotech.com/story/icahn-takes-control-of-imclone-as-ceo-departs/2006-10-25
[2] http://news.moneycentral.msn.com/provider/providerarticle.aspx?feed=AP&Date=20070215&ID=6490780
[3] http://www.fiercebiotech.com/story/spotlight-medimmune-touts-new-flumist-version/2005-06-16
[4] http://www.fiercebiotech.com/story/fda-approves-refrigerated-formulation-of-flumist/2007-01-08
[5] http://www.fiercebiotech.com/story/medimmune-gets-nod-for-new-vaccine-tech/2006-07-07